In a study by Camgoz et al., a tyrosine kinase inhibitor, nilotinib, was found to induce apoptosis in human chronic myeloid leukemia (CML) cells through upregulation of ceramide synthase genes and downregulation SK1 [195]. Here, TLCD3B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.